Based on ratings from 0 stock analysts, the Elevation Oncology, Inc. stock price is expected to increase by 1288.89% in 12 months. This is calculated by using the average 12-month stock price forecast for Elevation Oncology, Inc.. The lowest target is $5 and the highest is $10. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned ELEV 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Elevation Oncology, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ELEV. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ELEV.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $6 | Reiterates | Aug 7, 2024 |
Silvan Tuerkcan JMP Securities | Market Outperform | $7 | Reiterates | Jul 15, 2024 |
Silvan Tuerkcan JMP Securities | Market Outperform | $7 | Reiterates | Jun 28, 2024 |
Biren Amin Piper Sandler | Overweight | $10 | Initiates | May 31, 2024 |
Sudan Loganathan Stephens & Co. | Overweight | $8 | Initiates | May 14, 2024 |
Robert Driscoll Wedbush | Outperform | $8 | Reiterates | May 3, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $6 | Reiterates | Apr 9, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $6 | Reiterates | Mar 7, 2024 |
Silvan Tuerkcan JMP Securities | Market Outperform | $7 | Reiterates | Mar 7, 2024 |
Robert Driscoll Wedbush | Outperform | $8 | Maintains | Mar 7, 2024 |
Silvan Tuerkcan JMP Securities | Market Outperform | $7 | Initiates | Mar 1, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $6 | Maintains | Feb 20, 2024 |
Robert Driscoll Wedbush | Outperform | $5 | Reiterates | Nov 6, 2023 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $1.5 | Initiates | Sep 29, 2023 |
Robert Driscoll Wedbush | Outperform | $6 | Maintains | Jun 5, 2023 |
Andrew Berens SVB Securities | Outperform | $8 | Upgrade | May 30, 2023 |
Robert Driscoll Wedbush | Outperform | $4 | Reiterates | Mar 10, 2023 |
Andrew Berens SVB Leerink | Market Perform | $1 | Maintains | Jan 9, 2023 |
Anupam Rama JP Morgan | Underweight | Downgrade | Nov 10, 2022 | |
Andrew Berens SVB Leerink | Market Perform | $2 | Downgrade | Nov 7, 2022 |
When did it IPO
2020
Staff Count
29
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Joseph J. Ferra Jr.
Market Cap
$35.5M
In 2023, ELEV generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ELEV's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - On September 30, 2024, Empery Asset Management acquired 4,000,000 shares of Elevation Oncology Inc at $0.5999 per share, increasing its stake in the biotechnology firm.
Why It Matters - Empery Asset Management's purchase of 4 million shares in Elevation Oncology signals confidence in the company's future, potentially influencing market sentiment and stock performance.
Summary - Elevation Oncology (ELEV) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
Why It Matters - Elevation Oncology's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock price upward.
Summary - Elevation Oncology's EO-3021 received FDA Fast Track designation for treating advanced gastric and gastroesophageal junction cancer, targeting patients with Claudin 18.2 expression.
Why It Matters - FDA Fast Track designation for EO-3021 enhances Elevation Oncology's market position, potentially accelerating its drug development timeline and improving revenue prospects in a niche cancer treatment market.
Summary - Elevation Oncology, Inc. (Nasdaq: ELEV) has made a key announcement regarding its focus on developing selective cancer therapies for solid tumors with unmet medical needs.
Why It Matters - Elevation Oncology's announcement could indicate advancements in cancer therapies, potentially impacting stock performance and investor sentiment in the biotech sector.
Summary - Recent stock ideas highlight Easterly Government Properties as a reliable income source akin to Treasury bonds, while Bunge Global shows potential for market expansion despite a Q2 decline.
Why It Matters - Stocks with less coverage may present undervalued opportunities. Easterly Government Properties offers stable income, while Bunge Global's growth potential may attract long-term interest.
Summary - Elevation Oncology Inc. (ELEV) shares fell after the company released initial data from its Phase 1 trial of EO-3021 for advanced solid tumors expressing Claudin 18.2.
Why It Matters - The decline in Elevation Oncology's stock reflects market concerns over the Phase 1 trial data for EO-3021, potentially impacting future funding and investor confidence.